An interventional study of A strategy of first choice supraglottic airway and A strategy of first choice endotracheal intubation in Cardiac Arrest and Respiratory Failure, sponsored by Montefiore Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.
Among the 171 studies in Heart Arrest with a site in United States, this one is the 24th largest by enrollment of the 117 interventional ones that give a count, is one of 10 that started in 2023, is one of 67 with no phase, and was the 127th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
Mayo Clinic · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 0 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 12 · Phase 4 4
First in 2002; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,083 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 72 across the 117 interventional studies, 157 across the 54 observational. Of the 114 that completed or were terminated, 50 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 171 have an industry lead sponsor. The 10 most frequent:
Montefiore Medical Center is the lead sponsor of 417 studies on the registry; 69 are open to participants now.
Of its 89 completed or terminated interventional studies of FDA-regulated products, 77 (87%) have results posted.
Montefiore Medical Center has 2 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
17 of the studies in Heart Arrest with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283850Phase 3Carol BernierSurviving PEA in Roanoke (SPEAR) Study | 2027-02 |
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT02664831MaineHealthImmunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS) | 2027-01 |
| NCT07656259Mayo ClinicCOMPARE-VENT Feasibility Pilot Study | 2027-02-28 |
Add all 17 to your calendar (.ics) → With an account.
Among the 171 studies in Heart Arrest with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Hospital Airway Resuscitation Trial (HART) is a cluster-randomized, pragmatic trial of advanced airway management with a strategy of first choice supraglottic airway vs. first choice endotracheal intubation during in-hospital cardiac arrest.
In-hospital cardiac arrest occurs in nearly 300,000 hospitalized patients in the United States each year and results in substantial morbidity and mortality. Nevertheless, the evidence base guiding the management of in-hospital cardiac arrest is quite limited and society guidelines generally extrapolate data from the out-of-hospital cardiac setting to inform in-hospital arrest care. As compared to out-of-hospital arrest, however, in-hospital arrest victims tend to have more medical comorbidities, have a witnessed arrest, and be attended to by professional first responders with advanced monitoring and treatment capabilities. Advanced airway management is a key element of cardiac arrest resuscitation. The American Heart Association makes broad recommendations regarding airway management during in-hospital cardiac, supporting endotracheal intubation (a complex procedure requiring placement of an endotracheal tube through the vocal cords) and supraglottic airway placement (a less complex advanced airway modality wherein the device is placed blindly in the supraglottic space). Data from the out-of-hospital cardiac arrest setting has found that a supraglottic airway strategy may be similar or superior to a more complex endotracheal intubation strategy. There is no randomized data to guide practice in the in-hospital setting. We intend to address this knowledge gap by performing the Hospital Airway Resuscitation Trial (HART)-a highly-innovative, pragmatic cluster-randomized trial leveraging the unified clinical and research infrastructure within the Montefiore HealthSystem (New York City) to conduct a first-of-its-kind in-hospital arrest trial in a highly diverse patient population. Specifically, a mixture of academic and community hospitals within the MontefioreHealth system will be randomized to either a strategy of first-choice endotracheal intubation or a strategy of first choice supraglottic airway, with crossovers occurring at regular intervals. Key outcomes for the trial will include return of spontaneous circulation, alive-and-ventilator-free days, and hospital survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A strategy of 'first choice' supraglottic airway during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
Procedure: A strategy of first choice supraglottic airway · Procedure: A strategy of first choice endotracheal intubation
A strategy of 'first choice' endotracheal intubation during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
Procedure: A strategy of first choice supraglottic airway · Procedure: A strategy of first choice endotracheal intubation
See description in Arms section
See description in Arms section
Alive-and-ventilator free days
The number of days a patient is alive and breathing independently of invasive mechanical ventilation will be summarized by study arm using basic descriptive statistics. A patient who leaves the hospital alive and is not discharged to a hospice setting, will be considered to have lived to 28-days. A patient discharged to a hospice facility will be assessed as having died on the day of hospital discharge. A patient who is discharged on invasive mechanical ventilation, will be assumed to have remained on invasive mechanical ventilation through 28-days.
Time frame: From cardiac arrest until 28-days after cardiac arrest
Return of spontaneous circulation (ROSC)
ROSC will be assessed. ROSC is defined as having ≥20 minutes of continuous spontaneous circulation without chest compressions. Rates of ROSC will be summarized by study arm using basic descriptive statistics.
Time frame: Onset of in-hospital cardiac arrest event until either ROSC or death up to 24 hours
72 hour survival
Survival to 72 hour after in-hospital cardiac arrest (IHCA) event will be summarized by study arm using basic descriptive statistics.
Time frame: From IHCA event until 72 hours after IHCA event
28 day survival
Survival to 28 days after cardiac IHCA event will be summarized by study arm using basic descriptive statistics.
Time frame: From IHCA event until 28 days after IHCA event
Functional Outcome at Discharge
Functional Outcome at Discharge will be measured using the modified Rankin Scale (mRS). The mRS is a clinical tool that measures the patient's function disability (ability to perform daily living activities). The mRS is based on a 7-point scale ranging from 0 ("No symptoms at all") to 6 ("Death") such that higher scores are associated with increased functional disability. Scores at discharge can be used as a proxy to help identify patients who may require closer follow-up given the difficulty in obtaining long-term follow-up. mRS scores will be dichotomized to identify all patients with mRS\>3 and summarized by study arm.
Time frame: Time of hospital discharge
Survival to hospital discharge
Survival to hospital discharge, truncated at 60 days for the purposes of this outcome, will be summarized by study arm using basic descriptive statistics.
Time frame: From IHCA event until 60 days after cardiac arrest
Prolonged pauses
The number of prolonged pauses, defined as pauses lasting \>5 seconds in duration, in chest compressions during active Cardiopulmonary Resuscitation (CPR) will be determined. Prolonged pauses will be summarized by study arm using basic descriptive statistics.
Time frame: From start of chest compressions during cardiac arrest until ROSC or death up to 24-hours
Rate of ventilator-associated pneumonia (VAP)
Rate of VAP in the 7 days after cardiac arrest. VAP defined as new pneumonia while receiving mechanical ventilation after cardiac arrest. New pneumonia will be defined by 1) new pulmonary infiltrate on chest imaging 2) either new/worsening fever or leukocytosis 3) either change in sputum composition/frequency or worsening gas exchange or new/worsening cough or dyspnea. Rates of VAP will be summarized by study arm using basic descriptive statistics.
Time frame: Cardiac arrest until 7 days after cardiac arrest
Chest compression fraction
Percentage of total cardiac arrest time during which chest compressions are being performed will be determined. Results will be summarized by study arm using basic descriptive statistics.
Time frame: From start of chest compressions during cardiac arrest until ROSC or death up to 24-hours
Time to advanced airway
Time from initiation of chest compressions to advanced airway placement
Time frame: Time from initiation of chest compressions to advanced airway placement
Longest Overall Pause in Chest Compression
The duration of the longest overall pause in chest compression will be determined. This interval will be summarized by arm using basic descriptive statistics. It is hypothesized that supraglottic airway (SGA) placement will result in chest compression pauses of shorter durations.
Time frame: At time of cardiac arrest, less than one day
Number of Overall Pauses in Chest Compression
The number of overall pauses in chest compression, greater than 5 seconds in duration, will be summarized by arm using basic descriptive statistics. It is hypothesized that SGA placement will result in fewer chest compression pauses
Time frame: At time of cardiac arrest, less than one day
Time to epinephrine
Time from initiation of chest compressions to first epinephrine for cardiac arrest with initial non-shockable rhythm
Time frame: Time from initiation of chest compressions to first epinephrine for cardiac arrest with initial non-shockable rhythm
Plan to share: Yes — De-identified individual participant data collected during the trial will be shared through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), in accordance with NHLBI data sharing policy. More detailed data may be made available on request for collaboration, peer review, or other appropriate purposes. All sharing will comply with applicable patient confidentiality regulations. Resource Sharing: Key resources, including methodologies and statistical practices, will be made available in the form of peer-reviewed publications during the trial period. The HART investigators will additionally be open to queries from other investigators regarding elements of the trial.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available through BioLINCC no later than 3 years after the end of enrollment of the last participant.
Access criteria: Access is through BioLINCC's standard request process. Requests for more detailed data beyond the BioLINCC deposit may be made to the study investigators and will be considered for collaboration, peer review, or other appropriate purposes, subject to confidentiality protections.
Data sharing details ↗ · biolincc.nhlbi.nih.gov
Ran from Feb 2023 to primary completion in Aug 2026, 41 months.
Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's 41 months is above that.
Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jan 2027 → Aug 2026 and completion Feb 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.